InnoCare Pharma (SHA:688428, HKG:9969) obtained approval for zurletrectinib from China's National Medical Products Administration, a Thursday Hong Kong bourse filing said.
The drug is for the treatment of adult and adolescent patients with solid tumors harboring NTRK gene fusions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments